

SILVERBROOK RESEARCH Pty Ltd

393 Darling Street Balmain NSW 2041 Australia PO Box 207 Balmain NSW 2041 Australia Phone: +61 2 9818 6633 Fax: +61 2 9818 6711 Email: info@silverbrook.com.au EMAN 066 573 671

16 July 2008

Commissioner of Patents and Trademarks United States Patent and Trademarks Office WASHINGTON DC 20231 USA

Attention: Certificates of Correction Branch

Dears Sir

United States Patent No. 7,132,056 (10/728,944) Inventors/Assignors: Kia Silverbrook Assignee: SILVERBROOK RESEARCH PTY LTD Docket No. ZE009US

Attached is a form PTO/SB/44 requesting correction to "Claim 1" of the Patent Deed, for the above mentioned patent.

As these corrections do not result from errors caused by the applicant, no fee has been submitted

We look forward to the corrections in due course

Yours faithfully

Kia Silverbrook

Attchs.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO · 7.132.056 (10/728.944)

DATED : November 07, 2006

INVENTOR(S):

Kia Silverbrook.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 50, line 24 (claim 1) to read:

-- the drive circuitry and a fluid ejection member that is --

Column 50, line 35 (claim 1) to read:

-- etching the layer of sacrificial material to define deposi- --

Column 50, line 48 (claim 1) to read:

-- ejection ports; and

and L

Kia Silverbrook Managing Director Silverbrook Research Pty Ltd

Mr Kia Silverbrook
Mailing address of sender

Mr Kia Silverbrook
Silverbrook Research Pty Ltd

393 Darling Street Balmain NSW 2041 Australia PATENT NO. 7,132,056

No of additional copies

⇒

Burden Hour Statement. This form is estimated to take 1.0 hour to complete Time will vary depending upon the needs of the individual case. Any comment on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patient and Trademark Office, Washington, DC 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO. Assistant Commissioner for Patients, Washington, DC 20231